{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:55:22Z","timestamp":1762988122848,"version":"3.45.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023449","name":"UK Coronavirus Immunology Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_12014\/1"],"award-info":[{"award-number":["MC_UU_12014\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/R004250\/1","BB\/R019843\/1"],"award-info":[{"award-number":["BB\/R004250\/1","BB\/R019843\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.xcrm.2022.100739","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:09:52Z","timestamp":1661422192000},"page":"100739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people"],"prefix":"10.1016","volume":"3","author":[{"given":"Helen","family":"Parry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Bruton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reni","family":"Ayodele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Sylla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"McIlroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Willett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100739_bib1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100739_bib2","doi-asserted-by":"crossref","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20 133\u00a0UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2022.100739_bib3","unstructured":"Average age of death (median and mean) of persons whose death was due to\u00a0COVID-19 or involved COVID-19, by sex, deaths registered up to week\u00a0ending 2 October 2020, England and Wales - Office for National Statistics. (2020). https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/adhocs\/12376averageageofdeathmedianandmeanofpersonswhosedeathwasduetocovid19orinvolvedcovid19bysexdeathsregistereduptoweekending2october2020englandandwales."},{"key":"10.1016\/j.xcrm.2022.100739_bib4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100739_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12979-021-00246-9","article-title":"Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people","volume":"18","author":"Parry","year":"2021","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.xcrm.2022.100739_bib8","doi-asserted-by":"crossref","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2022.100739_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.xcrm.2022.100739_bib10","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6\u00a0months","volume":"385","author":"Levin","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T\u00a0cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100739_bib12","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2666-7568(21)00169-0","article-title":"Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6\u00a0weeks post vaccine in participants aged 80 years or older: an exploratory analysis","volume":"2","author":"Parry","year":"2021","journal-title":"Lancet. Healthy Longev."},{"key":"10.1016\/j.xcrm.2022.100739_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.xcrm.2022.100739_bib14","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","article-title":"Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"30","author":"Tauzin","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.xcrm.2022.100739_bib16","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"Payne","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100739_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jama.2021.21921","article-title":"Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals","volume":"327","author":"Grunau","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2022.100739_bib18","first-page":"1","article-title":"Extended interval BNT162b2 vaccination enhances peak antibody generation in older people","volume":"7","author":"Parry","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.xcrm.2022.100739_bib19","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for greater than six months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100739_bib20","doi-asserted-by":"crossref","first-page":"eabf8891","DOI":"10.1126\/sciimmunol.abf8891","article-title":"Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence","volume":"5","author":"Hartley","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2022.100739_bib21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41590-021-00902-8","article-title":"Robust SARS-CoV-2-specific T\u00a0cell immunity is maintained at 6\u00a0months following primary infection","volume":"22","author":"Zuo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100739_bib22","article-title":"Broad and strong memory CD4 + and CD8 + T\u00a0cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients","author":"Peng","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2022.100739_bib23","doi-asserted-by":"crossref","first-page":"e69375","DOI":"10.7554\/eLife.69375","article-title":"mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant","volume":"10","author":"Parry","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2022.100739_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2","volume":"590","author":"O\u2019Driscoll","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100739_bib25","doi-asserted-by":"crossref","first-page":"112342","DOI":"10.1016\/j.envres.2021.112342","article-title":"Change in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination","volume":"204","author":"Pastorino","year":"2022","journal-title":"Environ. Res."},{"key":"10.1016\/j.xcrm.2022.100739_bib26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib27","doi-asserted-by":"crossref","first-page":"eabo2202","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2022.100739_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100739_bib29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection (Infectious Diseases (except HIV\/AIDS))","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100739_bib32","article-title":"Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England","author":"Amirthalingam","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.xcrm.2022.100739_bib33","unstructured":"Interim clinical considerations for use of COVID-19 vaccines | CDC (2022). https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html."},{"key":"10.1016\/j.xcrm.2022.100739_bib34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6\u00a0months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100739_bib35","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s40121-021-00521-8","article-title":"Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals","volume":"10","author":"Jaganathan","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.xcrm.2022.100739_bib36","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41590-021-00969-3","article-title":"Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8+ T\u00a0cells","volume":"22","author":"Cupovic","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100739_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100739_bib38","article-title":"Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study","author":"Stowe","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.xcrm.2022.100739_bib39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41467-017-01475-7","article-title":"IL-2 imprints human naive B cell fate towards plasma cell through ERK\/ELK1-mediated BACH2 repression","volume":"8","author":"Hipp","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100739_bib40","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health. Eur."},{"key":"10.1016\/j.xcrm.2022.100739_bib41","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 Months after the second dose of mRNA-1273 vaccine for covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100739_bib42","doi-asserted-by":"crossref","first-page":"778679","DOI":"10.3389\/fimmu.2021.778679","article-title":"Impaired functional T-cell response to SARS-CoV-2 after two doses of BNT162b2 mRNA vaccine in older people","volume":"12","author":"Demaret","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100739_bib43","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100739_bib44","doi-asserted-by":"crossref","first-page":"e1010022","DOI":"10.1371\/journal.ppat.1010022","article-title":"Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination","volume":"17","author":"Davis","year":"2021","journal-title":"PLoS Pathog."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122002889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122002889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:52:43Z","timestamp":1762987963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379122002889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666379122002889"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100739","relation":{},"ISSN":["2666-3791"],"issn-type":[{"type":"print","value":"2666-3791"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100739"}}